Vernalis Research

Vernalis Research is a world leader in structure- and fragment-based drug discovery. We have generated six development candidates in the past six years and cell active lead compounds against 15 different targets. Our successes include projects in close collaboration with companies such as Lundbeck, Novartis, Servier, Genentech, Asahi Kasei Pharma and Taisho. Our strengths are in developing and applying the most appropriate structure-based methods to work with our partners to solve problems in drug discovery.

For more information please visit www.vernalis-research.com

 

Latest News

Servier and Vernalis plc announce achievement of 3 milestones in their oncology drug discovery collaboration

Servier and Vernalis plc are pleased to announce the achievement of two research milestones and one clinical milestone in their oncology drug discovery collaboration, triggering a total payment of €2 million to Vernalis.

 

Read more ...

At a glance

More information on Vernalis and its pipeline ...

FactsheetNov14 Company fact sheet

Comm thumbnail Explore the pipeline ...

Contact Vernalis

T: 0118 938 0000
F: 0118 938 0001

Contact information
Maps and directions
Contact form

To report SUSPECTED ADVERSE REACTIONS, contact Vernalis Therapeutics, Inc. at 1-855-705-9546 and drugsafety@propharmagroup.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch